Lon Cardon is the Chief Scientific Officer of BioMarin Pharmaceutical, focusing on rare genetic diseases. He joined BioMarin following 10 years at GlaxoSmithKline as a senior vice president of genetics, alternative drug discovery and target sciences, ultimately serving as chairman of the Discovery Board for GSK Research. Prior to his time at GSK, he was a professor at the University of Oxford until 2006 and then a professor of biostatistics and human biology at the University of Washington and the Fred Hutchinson Cancer Research Center.
He is a past council member of the NIH/National Human Genome Research Institute and a present advisor to the All of Us Precision Medicine Initiative. He was a board member and institutional founder of the Altius Institute for Biomedical Sciences, Centre for Therapeutic Target Validation (now Open Targets) and the GSK/Avalon Center of Excellence.
Lon received his Ph.D. from the University of Colorado, Boulder and did his postdoctoral training at Stanford University. He is an elected fellow of the UK’s Academy of Medical Sciences and the American Association for the Advancement of Science. He has published more than 225 articles, reviews, books and chapters on the genetics of common and rare diseases.